Cargando…

Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial—a study protocol of clinical trial

BACKGROUND: Ovarian clear cell carcinoma (OCCC) has an abysmal prognosis with a median overall survival (OS) of 25.3 months because of a low response to chemotherapy. The 5-year disease-specific survival rate after recurrence is 13.2%, with more than two-thirds of the patients dying within a year. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ruyuan, Liu, Xingyu, Song, Chunyan, Zhang, Wei, Liu, Jiahao, Jiao, Xiaofei, Yu, Yang, Zeng, Shaoqing, Chi, Jianhua, Zhao, Yingjun, Ma, Guanchen, Huo, Yabing, Li, Ming, Peng, Zikun, Li, Guiling, Jiang, Jie, Gao, Qing-Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131073/ https://www.ncbi.nlm.nih.gov/pubmed/35613822 http://dx.doi.org/10.1136/bmjopen-2021-058132

Ejemplares similares

Oncological big data platforms for promoting digital competencies and professionalism in Chinese medical students: a cross-sectional study
por: Liu, Jiahao, et al.
Publicado: (2022)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
por: Liu, Xingyu, et al.
Publicado: (2023)

Implementation of a Cardiogenic Shock Team and Clinical Outcomes (INOVA-SHOCK Registry): Observational and Retrospective Study
por: Tehrani, Behnam, et al.
Publicado: (2018)

Development and validation of a nomogram to predict cancer-specific survival of mucinous epithelial ovarian cancer after cytoreductive surgery
por: Ma, Guanchen, et al.
Publicado: (2023)

COVD-13. EFFECTS OF COVID-19 PANDEMIC ON NEUROSURGICAL ONCOLOGY PRACTICES AT INOVA HEALTH SYSTEM: AN INSTITUTIONAL EXPERIENCE
por: Dang, Danielle, et al.
Publicado: (2020)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
por: Gong, Hongyu, et al.
Publicado: (2023)

Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2021)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
por: Zhou, Ting, et al.
Publicado: (2022)

A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
por: Zeng, Xianghua, et al.
Publicado: (2023)

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
por: Fang, Xuefeng, et al.
Publicado: (2023)

Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial
por: Chen, Yi-Xing, et al.
Publicado: (2023)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Peng, Ye, et al.
Publicado: (2022)

Osteoblastic Bone Reaction Developing During Treatment With Sintilimab and Bevacizumab in a Patient With KRAS(G12V)-Mutant Lung Adenocarcinoma
por: Chen, Chang Jun, et al.
Publicado: (2023)

Sintilimab: Pneumonitis: case report
Publicado: (2021)

Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study
por: Que, Yi, et al.
Publicado: (2023)

Efficacy and Safety Evaluation of Sintilimab for Cancer Treatment: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Ye, Ziqi, et al.
Publicado: (2022)

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
por: Wei, Wei, et al.
Publicado: (2022)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study
por: Lu, Nian, et al.
Publicado: (2023)

Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
por: Tian, Zhichao, et al.
Publicado: (2022)

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients
por: Chen, Jinzhang, et al.
Publicado: (2020)

Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR‐mutated non‐small cell lung cancer patient: A case report
por: Zhang, Yiruo, et al.
Publicado: (2020)

Sintilimab for the treatment of non-small cell lung cancer
por: Zhang, Lin, et al.
Publicado: (2022)

Subconjunctival Bevacizumab for Primary Pterygium Excision; a Randomized Clinical Trial
por: Razeghinejad, Mohammad-Reza, et al.
Publicado: (2014)

Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort study
por: Liu, Dan, et al.
Publicado: (2020)

Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review
por: Huang, Xiaofei, et al.
Publicado: (2021)

Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
por: Chen, Xiaofeng, et al.
Publicado: (2023)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
por: Tao, Rong, et al.
Publicado: (2021)

Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial
por: Shao, Miner, et al.
Publicado: (2023)

Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
por: Jiang, Haiping, et al.
Publicado: (2020)

Recent updates on Sintilimab in solid tumor immunotherapy
por: Liu, Xuhong, et al.
Publicado: (2020)

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
por: Wang, Jie, et al.
Publicado: (2019)

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
por: Zhang, Zhi, et al.
Publicado: (2022)

Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial
por: Takano, Shingo, et al.
Publicado: (2014)

Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report
por: Lye, Ya-lei, et al.
Publicado: (2023)

Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)
por: Zhou, Nan, et al.
Publicado: (2023)

Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial
por: Guo, Chengxiang, et al.
Publicado: (2023)

Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
por: Zhang, Wen, et al.
Publicado: (2022)

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial
por: Pili, Roberto, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_53s0dsh3oveqqddt2hjb0m6h85